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A REVIEW AND PRACTICAL CONSIDERATIONS
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Purpose: Exercise cardiac rehabilitation (CR) represents an
evidence-based therapy for patients with heart failure with
reduced ejection fraction (HFrEF) and this article provides a
concise review of the relevant exercise testing and CR literature,
including aspects unique to their care.
Clinical Considerations: A hallmark feature of HFrEF is exercise intolerance (eg, early-onset fatigue). Drug therapies for
HFrEF target neurohormonal pathways to blunt negative remodeling of the cardiac architecture and restore favorable loading conditions. Guideline drug therapy includes β-adrenergic
blocking agents; blockade of the renin-angiotensin system; aldosterone antagonism; sodium-glucose cotransport inhibition; and
diuretics, as needed.
Exercise Testing and Training: Various assessments are used
to quantify exercise capacity in patients with HFrEF, including peak oxygen uptake measured during an exercise test and
6-min walk distance. The mechanisms responsible for the exercise intolerance include abnormalities in (a) central transport
(chronotropic response, stroke volume) and (b) the diffusion/
utilization of oxygen in skeletal muscles. Cardiac rehabilitation
improves exercise capacity, intermediate physiologic measures
(eg, endothelial function and sympathetic nervous system activity), health-related quality of life (HRQoL), and likely clinical
outcomes. The prescription of exercise in patients with HFrEF
is generally similar to that for other patients with cardiovascular
disease; however, patients having undergone an advanced surgical therapy do present with features that require attention.
Summary: Few patients with HFrEF enroll in CR and as such,
many miss the derived benefits, including improved exercise capacity, a likely reduction in risk for subsequent clinical events
(eg, rehospitalization), improved HRQoL, and adoption of disease management strategies.
Key Words: exercise prescription • exercise training • heart
failure

H

eart failure (HF) affects greater than 6.2 million Americans and as the population ages this number is increasing, with an estimated prevalence of 3% of the population by 2030.1 The lifetime risk of HF is greater than one
in five among patients aged 45-95 yr and risk is affected by
race and sex, with African American women experiencing
the highest risk.1 Clinical risk factors for developing HF are
similar to other cardiovascular diseases (CVDs) and include
hypertension, obesity, diabetes, and smoking, and account
for >50% of attributable risk.2 Spending across the spectrum of the disease accounts for $30 billion annually.3
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Exercise-based cardiac rehabilitation (CR) represents an
evidence-based therapy for patients with HF with reduced
ejection fraction (HFrEF).4 This article provides a concise,
minireview of the literature that focuses on important exercise testing and training/rehabilitation considerations for
patients with HFrEF. It also addresses several contemporary issues unique to patients with HFrEF who participate
in CR. This review does not address exercise training or
CR in patients with HF with preserved ejection fraction, for
such we refer readers to the review paper by Tucker et al.5
Heart failure is a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. In
patients with HFrEF this occurs due to a loss of systolic
function from any of a myriad of causes and is defined as
an ejection fraction <40%. Clinically, patients are typically
categorized across two different staging systems: American
College of Cardiology/American Heart Association (ACC/
AHA) stages A through D and New York Heart Association
(NYHA) functional classes I through IV.4 The ACC/AHA
stages are progressive and help guide timing for implementation of guideline-directed medical therapy, with patients
moving from being “at risk” of developing overt HF (stages
A and B), to “symptomatic” HF (stages C and D), and finally to those with “end-stage” disease (stage D). This staging system contrasts with the NYHA classifications, which
are dynamic and reflect the patient current symptom status
(eg, dyspnea on exertion and early-onset fatigue). Class I
represents no symptoms or limitation to ordinary activity;
class II reflects mild symptoms and a slight limitation of ordinary daily activities; class III represents a marked limitation of activities due to symptoms, but no symptoms at rest;
and class IV signifies symptoms even at rest. Objectively,
NYHA classes broadly reflect the following resting metabolic equivalents of task (MET): class I >7 METs, class II
5-7 METs, class III ≥2-4.9 METs, and class IV <2 METs.6
Therapies for HFrEF primarily target neurohormonal
pathways to blunt negative remodeling of the cardiac architecture and restore favorable cardiac loading conditions.
Currently, the ACC has assigned a level 1 recommendation to several different classes of drugs for use in patients
with chronic HFrEF, the data for each derived from large
randomized clinical trials that demonstrated improvement
in both morbidity and mortality.7 The backbone of drug
therapy lies with the use of (a) HFrEF-specific β-adrenergic blocking agents (so-called β-blockers); (b) blockade of
the renin-angiotensin system, preferably with sacubitrilvalsartan; (c) aldosterone antagonism; (d) most recently,
sodium-glucose cotransport inhibition; and (e) a diuretic
to reduce volume overload, as needed. After optimization
of the aforementioned therapies, evidence also supports
the use of hydralazine and nitrates in African American patients. Unfortunately, HFrEF is a progressive condition and
as such, many patients develop symptoms or intolerance
that is refractory to guideline-directed medical therapy,
which signifies end-stage disease (stage D, class IV). Therapy
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options for patients with ACC/AHA stage D HF is primarily limited to palliative measures for symptom relief; however, certain patients are candidates for advanced therapies
including cardiac transplantation or surgical implant of a
left ventricle assist device (LVAD).

REVIEW OF RELEVANT LITERATURE
EXERCISE TESTING
A graded exercise stress test or, preferably, a cardiopulmonary exercise test can be useful in patients with HFrEF
for a variety of reasons, including collection of the needed information to optimize and guide intensity of effort
during exercise training; quantifying change in cardiorespiratory fitness due to an exercise, device, or drug therapy; and measurement of exercise capacity to determine
candidacy for an advanced therapy. Regarding the safety
of exercise testing, Keteyian et al8 observed in a cohort
of younger patients with HFrEF (n = 2037, mean age:
59 yr) that safety is similar to that of other patients with
a CVD; there were no deaths and <0.5 nonfatal, major cardiovascular events requiring hospitalization/1000
tests.
Dating back to the seminal article by Mancini et al,9 the
use of the cardiopulmonary exercise test in HFrEF is backed
by >30 yr of data, much of which focused on using exercise
duration, peak oxygen uptake (V̇o2peak), and percent predicted V̇o2peak (ppV̇o2peak) to help stratify risk and determine
eligibility for an advanced therapy. Concerning the latter,
a cut-off for V̇o2peak has been set at 14 mL·kg−1·min−1 in
patients not on β-blockade therapy and 12 mL·kg−1·min−1
in those on a β-blocker.10 These values, however, rely on
patients achieving peak or maximal cardiometabolic stress
during exercise testing, with submaximal stress associated
with a respiratory exchange ratio (RER) <1.05, a value
that reflects a potentially incomplete shift in skeletal muscle cellular energy production from predominately aerobic
to anaerobic metabolism. Contemporary decision-making
for disease severity and candidacy for advanced therapies
now also include other exercise parameters,11-13 such as
(a) chronotropic response; (b) an assessment of ventilatory
efficiency (slope of minute ventilation to carbon dioxide
production, V̇E/V̇co2 slope), which when elevated reflects alveolar ventilation-perfusion mismatch; and (c) the presence
of an exercise oscillatory ventilation pattern, the etiology of
which is not fully understood but may be associated with
Cheyne-Stokes respirations seen during rest or sleep. These
parameters are particularly helpful in providing for a more
nuanced approach to risk stratification among patients classified as intermediate risk or those who achieve an RER
<1.05.
The Figure represents a clinical decision tool used at
Henry Ford Hospital, one that adapts prior work from
Corrà et al13 and Malhotra et al14 and incorporates most
of the above-identified variables. In this model a V̇E/V̇co2
slope >35 and/or the presence of exercise oscillatory ventilation can shift a patient into a higher risk category,
than is dictated by their V̇o2peak or ppV̇o2peak performance
alone.13-15
The assessment of exercise capacity, measured as V̇̇o2peak
using indirect, open circuit spirometry, is important because it
represents the ability of the body to transport (cardiac output)
and utilize (arteriovenous O2 difference [A-Vo2Diff]) oxygen.
In patients with HFrEF, V̇o2peak is reduced by ∼15-40% compared with age-matched healthy persons and typically ranges
between 10-18 mL·kg−1·min−1.16-18 This exercise intolerance
is a hallmark feature of patients with HFrEF, often inducing

a level of impairment that interferes with functional independence and activities of daily living.
Several pathophysiologic mechanisms are responsible
for the reduced exercise capacity in patients with HFrEF
(Table 1). These can be broadly categorized under central
or local factors and pertinent information about each is
briefly summarized next.
Central or Bulk Oxygen Transport
Impaired cardiac output reserve (up to 50% below normal)
during exercise is due to attenuation of the increase in stroke
volume,17-19 elevated filling pressures, marked chronotropic incompetence, and reduced heart rate (HR) reserve.19-21
Chronotropic incompetence is estimated to occur in up to
∼50% of patients with HFrEF.
Exercise intolerance is also associated with abnormalities
in the delivery of oxygen via the major conduit arteries (eg,
femoral and brachial),22 which includes an impaired ability
of the vascular endothelium to sufficiently induce vasodilation and increase blood flow during exertion. Hambrecht
et al23 reported that both resting and the endothelial dependent increase in femoral blood flow during exercise were
lower compared with age-matched controls, at −35% and
−84%, respectively. Interestingly, the pulsatile sheer stress
placed upon the endothelium of arterial walls, such as that
which occurs during regular exercise-based CR, is likely
responsible for the observed partial restoration of endothelial-dependent vasodilation.23,24
Local Diffusive Oxygen Transport and Oxygen
Utilization
Although a reduced exercise cardiac output is typically
cited as the primary reason for the exercise intolerance in
HFrEF, an abnormality in microvascular (arteriole, metarteriole) diffusive function (movement of oxygen from
hemoglobin in the microvascular and capillaries perfusing
the skeletal muscles to the mitochondria inside the muscles)
is involved as well, estimated to be up to 30% lower than
healthy normals.18,19 Additionally, the heightened or overactive neurohumoral axis that is common in patients with
HFrEF is associated with elevated sympathetic activity25

Figure. Decision algorithm used at Henry Ford Hospital for risk stratification using variables derived from a cardiopulmonary exercise test in
patients with heart failure with reduced ejection fraction, adapted from
Corrà et al,13 Malhotra et al,14 and Guazzi et al.15 ppVo2peak indicates
percent predicted peak oxygen uptake; RER, peak respiratory exchange
ratio; VE/Vco2, slope line of minute ventilation to carbon dioxide production; Vo2peak, peak oxygen uptake. Green color associated with low
risk (eg, >95% event-free survival at 1 yr) and yellow, orange, and red
colors associated with intermediate and higher (eg, >10% 1-yr mortality)
risk for a clinical event; the latter requiring more aggressive medical
management or possible advanced surgical therapies. This figure is
available in color online (www.jcrpjournal.com).
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Table 1
Abnormalities in the Factors Responsible for the Transport and Utilization of Oxygen During Maximal Exercise in
Patients With HFrEF (Compared With Normal)
HFrEF

Normal

Central or bulk oxygen transport (heart and large conduit arteries)
Cardiac output

↑/↑↑

↑↑↑

↑

↑↑

↑↑/↑↑↑

↑↑↑↑

↑/↑↑

↑↑↑

↑/↑↑

↑↑↑

Capillary density (capillaries per SM fiber)

↓

N

Percentage of type I aerobic or oxidative-type SM
fibers

↓

N

Percentage of type II anaerobic or glycolytic-type
SM fibers

↑

N

SM oxidative enzyme activity

↓↓

N

SM mitochondrial volume/density

↓↓

N

Stroke volume
Heart rate
Peripheral artery dilation (eg, femoral artery)
Local diffusive oxygen transport and oxygen utilization
Local, metabolically mediated microvascular dilation

Abbreviations: HFrEF, heart failure with reduced ejection fraction; N, normal; SM, skeletal
muscle; ↑, increase; ↓, decrease.

and increased plasma norepinephrine levels, both likely
contributing to this microvascular dysfunction.
Another important factor is an impaired ability of the
skeletal muscles to efficiently process the oxygen that it does
receive during exercise. Specifically, a reduction in the percentage of type I (so-called oxidative) muscle fibers; reduced
mitochondrial volume and function; a possible reduction in
the ratio between capillaries and individual muscle fibers;
and reductions in muscle size, strength, and endurance20,26,27
all likely contribute to early-onset fatigue in patients with
HFrEF. The mechanisms responsible for these skeletal muscle abnormalities are likely multifactorial, including (to some
extent) the well-recognized increases in pro-inflammatory
cytokines (eg, tissue necrosis factor-α, interleukin-6).28
Finally, in addition to the above central and local factors
that contribute to the exercise intolerance observed in these
patients, several common comorbidities are also known to
be involved, including sedentary behavior, obesity,29 and
atrial fibrillation. Regarding atrial fibrillation, its prevalence varies between 10% and >40%, the extent of which
is influenced greatly by the severity of the HF.30 Among
patients with HFrEF, Pardaens and colleagues31 observed
that exercise capacity (ie, V̇o2peak) was approximately 20%
lower in those with atrial fibrillation (13.8 mL·kg−1·min−1)
versus like patients in sinus rhythm (17.1 mL·kg−1 min−1).
EXERCISE-BASED CARDIAC REHABILITATION
Over the past 30 yr, literally dozens of single-site and multisite randomized trials and several meta-analyses have shown
that exercise training alone and exercise-based CR improve
various measures of exercise capacity, health-related quality of life (HRQoL), and clinical outcomes in patients with
HFrEF. Because of such, in 2014 the Centers for Medicare
& Medicaid Services expanded its coverage for CR to include Medicare beneficiaries with HFrEF.32 The broad and
systemic effects associated with exercise CR in patients with
HFrEF are briefly summarized next (see also Table 2).
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Exercise Capacity
Prior to 2009, numerous small, single-site trials involving
patients with HFrEF showed that regular exercise training
improves V̇o2peak, 6-min walk test (6MWT) distance, and
exercise duration between 10% and 30%.33,34 In 2009, the
82-site HF-ACTION trial reported that among 2331 patients with HFrEF (ejection fraction <35%) randomized to
36 sessions of supervised exercise training plus up to 1-yr of
home-based exercise versus usual care, after 3 mo of exercise training, exercise duration, 6MWT distance, and V̇o2peak
were significantly (all P < .001) increased 1.5 min, 20 m,
and 0.6 mL·kg−1·min−1, respectively.35 The magnitude of
the increase in V̇o2peak was less than what is typically reported from single-site trials, likely partly due to suboptimal adherence among patients in the exercise group. Using
patient-level data from eight trials, in 2019 the ExTraMATCH II Collaborative reported significant improvement
in 6MWT distance (mean difference: +24.0 m; 95% CI:
5.3-42.7) at 1 yr among exercise trained patients versus
controls.36 Several studies have evaluated higher-intensity
interval training in HFrEF, with the magnitude of the increase in V̇o2peak appearing to be larger (≥2 mL·kg−1·min−1)
in shorter-duration single-site trials24 versus longer-duration (1 yr) multi-site trials.37
Improvements in exercise tolerance (ie, 6MWT distance
and V̇o2peak) are likely due to a variety of mechanisms including (a) improved delivery of oxygen to the metabolically more active skeletal muscles (secondary to improved
chronotropic responsiveness and enhanced endothelial
function of the conduit arteries)23,24,38 and (b) partial restoration in the ability of the metabolically active skeletal
muscles to utilize oxygen—the latter due to improvement in
cellular histochemistry and increased muscle strength and
endurance.39 These changes are summarized in Table 2.
Clinical Outcomes
Per the HF-ACTION trial, the combined primary endpoint of all-cause mortality or hospitalization was nonsignificantly reduced in the exercise group versus usual care
(HR = 0.93: 95% CI, 0.84-1.02; P = .13).35 However,
following adjustment for highly prognostic, prespecified
baseline characteristics, exercise training was associated
with a significant 11% reduction in this same endpoint
(HR = 0.89: 95% CI, 0.81-0.99; P = .03). A subsequent meta-analysis using individual data from patients
with HFrEF (n = 3912) found no significant difference in
pooled time-to-event estimates for exercise training versus controls for all-cause mortality (HR = 0.83: 95% CI,
0.67-1.04) or all-cause hospitalization (HR = 0.90: 95%
CI, 0.76-1.06).40
Two secondary analyses from HF-ACTION are worth
mentioning. First, Keteyian et al41 showed that, among
patients randomized to the exercise training arm of that
trial, exercise volume (ie, MET-hr/wk) completed was a
significant, independent predictor of all-cause mortality or
hospitalization and cardiovascular mortality or HF hospitalization. Specifically, among patients who exercised as
prescribed and completed between 3 and 7 MET-hr/wk,
subsequent risk for clinical events was reduced ≥30%; 5
MET-hr/wk is equivalent to ∼30 min of walking at 2 mph,
4 times/wk. Second, Swank et al42 looked at the influence
of change in cardiorespiratory fitness on risk for clinical
events and reported that every 6% increase in Vo2peak was
associated with a 5% lower risk for all-cause mortality and
hospitalization (adjusted HR = 0.95: 95% CI, 0.93-0.98;
P < .001) and an 8% lower risk of CVD mortality or HF
hospitalization (adjusted HR = 0.92: 95% CI, 0.88-0.96;
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Table 2
Summary of Common Physiologic and Clinical Outcomes Due to Exercise Cardiac Rehabilitation in Patients With HFrEF
Outcome

Response or Adaptation

Comment

Exercise capacity (V̇o2peak, 6MWT distance, power
output or W, exercise duration)

Modest improvement typically observed across all
measures of cardiorespiratory fitness

V̇o2peak typically increased 10-20%
25- to 30-m increase in 6MWT distance

Cardiac function

Increase in peak cardiac output, with generally no change
or a mild increase in peak stroke volume
No change or mild increase in peak HR (up to 4-10 bpm)
No change or slight increase in resting ejection fraction
(3-5 percentage points)

Increase in peak HR observed most often in
patients not taking β-adrenergic blockade
therapy

Peripheral conduit artery (eg, brachial) function

Partial restoration or normalization of endothelialdependent vasodilatory function

Improvements in blood flow and vascular diameter

Skeletal muscle function

Partial restoration or normalization of muscle function

Improvements in mass, strength, and endurance
Improvement in mitochondrial oxidative enzyme
activity

Sympathetic nervous system activity

Reduced at both rest and during exercise, as measured
by muscle sympathetic nervous system activity
(bursts/min)

Near normalization of resting sympathetic nerve
activity
Reductions in plasma norepinephrine levels at
rest and during exercise

Health status and quality of life

For both the Kansas City Cardiomyopathy Questionnaire
and the Minnesota Living with Heart Failure
Questionnaire, consistent improvements in overall
score and in most submeasures

Modest reduction in depressive symptoms

Clinical outcomes

Modest reduction in risk for all-cause and HF-specific
hospitalization is likely
Likely no significant effect on risk for mortality

Volume of exercise completed is associated with
the magnitude of reduction in observed risk

Abbreviations: 6MWT, 6-min walk test; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; V̇o2peak, peak oxygen uptake.

P < .001). These two studies further strengthened the importance of engaging patients with HFrEF in a regular exercise-based CR regimen.
The saltatory effects of exercise training and CR in patients with HFrEF also extend to HRQoL and depression.
Specifically, ExTraMATCH II showed that exercise training improved HRQoL, as assessed by the Minnesota Living
with Heart Failure Questionnaire, versus controls (12-mo
follow-up: mean improvement 5.9 points; 95% CI, 1.010.9; P = .018).36 Additionally, depression is a common
comorbidity in patients with HFrEF, and Blumenthal and
coworkers43 noted that, among patients who report clinically significant depressive symptoms, depression scores
following both 3 mo and 12 mo of exercise training were
significantly reduced (both P < .05).
PRESCRIBING EXERCISE IN PATIENTS WITH HFrEF
Overall, there are only a few differences or concerns between the exercise prescription/programming methods for
patients with HFrEF and those for patients with other types
of CVD. The specifics associated with these concerns are
identified in Table 3 and mostly target the earlier-onset fatigue that is common in patients with HFrEF and the greater
comorbid burden that these patients often experience.
The above-notwithstanding, within the context of patients with HFrEF, it is appropriate to review the general tenets associated with prescribing exercise. Specifically, since a
primary reason for undertaking exercise training in patients
with HFrEF is to reverse exercise intolerance, the principle
of specificity of training dictates that large-muscle, wholebody (eg, walking and cycling) activities that stimulate the
cardiorespiratory system should be employed. Additionally,
three other factors (ie, intensity, duration, and frequency of

effort) must be considered to impose the necessary training
stimulus or overload44,45 (Table 3). As tolerated, the clinical
exercise physiologist or other exercise professional responsible for writing the exercise prescription and overseeing the
patient progression needs to ensure that the volume of exercise performed each week is slowly but consistently adjusted over time.45 For most patients with HFrEF, progressing
up to the initially targeted volume of exercise (eg, 5 METhr/wk) will require between 1-3 wk. Duration and frequency of effort should both be progressively uptitrated before
intensity.
With respect to exercise training intensity, the preferred
approach for prescribing such involves the HR reserve
method, which requires measured peak HR from a maximal
graded exercise stress test. However, such testing is not routinely completed by most patients enrolled in CR today.46
Should an exercise test be performed for CR or the risk
stratification purposes discussed previously, the HR-based
method outlined in Table 3 is applicable. In the absence
of an exercise stress test, the American College of Sports
Medicine recommends guiding exercise intensity at 11-14
on the Borg 6-20 rating of perceived exertion scale.44,45
Finally, since disorders of skeletal muscle strength, function, and endurance are common in patients with HFrEF, the
incorporation of resistance training into the overall exercise
regimen for selected patients is justified. Regarding such, it
is prudent to consider the methods advanced for healthy
individuals and patients with other CVD (Table 3).47

DISCUSSION AND SPECIAL CONSIDERATION
Even though CR is an evidence-based guideline recommendation for patents with HFrEF,4 literally hundreds of
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Table 3
Summary of Exercise Prescription for Patients With Heart Failure Using the FITT Principle
Frequency

Intensity

Time (Duration)

Cardiorespiratory

Progress from 3 to
5 d/wk

If data from an exercise stress test is available, use
HR-reserve method set at 60-80%
If data from a stress test is not available, set
intensity at an RPE of 11-14 (using 6-20 Borg
scale)

Progressively increase
to ≥30 min/session
In selected patients,
consider higherintensity interval

Treadmill, free walking, cycle
ergometer, dual-action seated
stepper, and arm ergometer

Resistance

1-2 nonconsecutive
d/wk

Begin with 40% of 1 RM for upper body lifts and
50% of 1 RM for lower body lifts; progress both
to 70% of 1 RM over time
Alternately, guide lift intensity by RPE, between 11
and 13 on a 6- to 20-point scale

One to two sets for
each of the involved
muscle groups
Higher repetition and
lower weight model;
10-15 repetitions/set

Use fixed weight machines, hand
weights, bands/tubing, or body
weight exercises
Six to eight primary regional exercises

Training Method

Type (Modality)

Special considerations:
• It is common for patients with HFrEF to experience early-onset fatigue during the first 1-3 wk of CR; consider starting with 10-min bouts of exercise, progressing
up to the planned amount of 30-40 min/session as tolerated; progress duration before exercise intensity.
• Multiple comorbidities (atrial fibrillation, obesity, renal disease, and diabetes) are common in patients with HFrEF and as a result, attendance to CR is often
interrupted because of such; reinforce with patients the importance of attending CR when they are well enough to do so.
• Frailty and marked impairments of balance, mobility, and strength are very common in patients with HFrEF; adopt a multidisciplinary approach (nursing, exercise
physiology, and physical therapy) to ensure physical rehabilitation extends beyond improving cardiorespiratory fitness alone; strive to improve daily physical
function, improve cognition, and reduce injuries and falls.
• For patients able to engage in higher-intensity interval training, set work intervals at 80-90% of HR-reserve or RPE of 14-15 and recovery intervals at 60-70% of
HR reserve or RPE of 11-12; set ratio of work-recovery intervals at 1 min:1 min or 4 min:3 min.
• In patients with a left ventricular assist device, resistance training should be limited to bands/tubing only, avoid activities that involve trunk flexion (eg, sit-ups),
and focus should be on improving leg strength with body resistance activities (eg, wall sits and toe raises). If the patient is pacemaker independent and results
of recent exercise stress test are available, then an HR-based approach is appropriate to guide exercise intensity; use RPE if exercise stress test data are not
available or the patient is pacemaker dependent.
• In patients with atrial fibrillation or those having undergone cardiac transplant, guide exercise intensity using RPE of 11-14 only.
Abbreviations: CR, cardiac rehabilitation; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; RM, repetition maximum; RPE, rating of perceived exertion.

thousands of patients each year do not initiate and benefit
from such a therapy. For example, among the more than
397 000 Medicare beneficiaries with HF who were eligible for CR in 2017, only 2.6% completed ≥1 CR session
sometime during the subsequent 12 mo; in these CR patients the average number of sessions completed was 22 and
20% completed all 36 allowable sessions.48 This data are
especially troublesome because patients with HF are often
older, representing a cohort at increased risk for mortality
and presenting with multiple morbidities (eg, frequent hospitalizations and frailty). As such, they are well positioned
to benefit from a CR program that provides age-appropriate programming (eg, strength/balance/multi-component
training, and tai chi).49,50 We concur with the recent callto-action that “clinicians, health care leaders, and payers
should prioritize incorporating CR as part of the standard
of care for patients with HF.”20
Much of the above material has focused on the delivery of traditional CR-related care to patients with HFrEF.
There are, however, other important issues that need to be
considered relative to providing high-quality and contemporary patient care to patients with HFrEF in CR. These
issues are addressed next.
STARTING CARDIAC REHABILITATION AND SELF-CARE
DISEASE MANAGEMENT
Cardiac rehabilitation, by its very nature, delivers much of
the self-care education and CVD management (eg, medication compliance) care that is known to benefit patients with
HF (Table 4).51,52 That said, the timing of enrolling patients
with HFrEF into CR is hampered by Medicare policy, in that

www.jcrpjournal.com

it will only pay for exercise CR sessions that are completed
after the patient has waited 6 wk after an HF-related hospitalization. Although some patients may require the full
6-wk period (or more) to become clinically stable to engage
in supervised exercise, many others are clinically stable,
behaviorally engaged, and internally motivated and ready
to start exercise CR before the 6-wk waiting period has
passed. Thus, CR programs should strive to begin engaging
all eligible patients with HFrEF either during their hospitalization53 or within 2-3 wk after hospital discharge, with
the plan to complete any preprogram orientation requirements and begin program-offered patient education and
self-management activities so that when 6 wk after hospital discharge has elapsed, the patient can attend their first
billable CR exercise session. Additionally, Davidson et al54
incorporated a structured HF-specific disease management
component into CR and at 12-mo follow-up, patients in the
intervention group experienced significant reductions in allcause hospital readmissions (44 vs 69%, P = .01), cardiac
readmissions (24 vs 55%, P = .001), and all-cause mortality (7 vs 21%, P = .03).
ADVANCED THERAPIES
Most CR programs today enroll patients who received an
advanced HF therapy, such as mechanical support (ie, LVAD)
or cardiac transplant. Although the exercise training practices for these patients in CR are quite similar to those for
other patients with a CVD, there are differences worth mentioning. For patients with an LVAD: (a) withhold exercise if
seated Doppler blood pressure prior to exercise, which approximates mean arterial pressure, is <60 or > 110 mm Hg;
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Table 4
Common Self-care Disease Management Behaviors for
Patients With Heart Failurea
• Maintain compliance with any provider requested sodium restriction
(eg, <2 g · d−1)
• Maintain compliance with any provider requested fluid restriction
(eg, <2 L · d−1)
• Establish and reinforce a system or process for medication compliance
• Inform provider of any self-prescribed dietary supplements, including
nutraceuticals
• Acquire an accurate scale for daily measurement of body weight; monitor
for excessive weight change (eg, ≥2 lb in 1 d or 5 lb in 7 d)
• Monitor breathing for having to prop oneself up with more pillows to sleep
or worsening shortness of breath while eating, talking, walking, or getting
dressed
• Monitor for other signs/symptoms of worsening heart failure (eg, swelling in
abdomen, less alert, and having to sleep sitting up)
• Abstain from tobacco products and recreational drugs; avoid secondhand
tobacco smoke
• Establish treatment for sleep disturbance and heavy snoring, if needed
• Establish treatment for depression and anxiety, if needed
• Maintain vaccinations/immunizations (COVID-19, influenza, and
pneumococcal pneumonia)
• Maintain a schedule of planned physical activity/exercise (eg, 150 min/wk
of moderate-intensity exertion)
• Attend/keep all scheduled in-person or telehealth appointments with
providers
a

Adapted from Heindenreich et al,4 Ades et al51 and Riegel et al.52

(b) limit resistance training to resistance bands or light hand
weights (10-15 repetitions/set); (c) avoid extensive trunk
flexion (sit-ups, leg lifts) to both avoid a potentially harmful increase in intra-abdominal pressure and avoid infection/
maintain integrity at the site where the driveline exits the
skin; (d) limit lower body resistance exercises that target increasing leg strength to sit-to-stand activities or partial wall
squats; and (e) extend cooldown periods and consider hydration during recovery to avoid provocation of hypotension,
dizziness/orthostasis, or device low flow alarms related to
blood pressure dysregulation or dehydration.55
Regarding patients who have undergone cardiac transplant and are clinically stable, there is no policy that they
too must wait 6 wk before starting CR, but there are some
unique issues pertinent to their participation. These are: (a)
because the transplanted heart is decentralized from the
autonomic nervous system, use of an HR-based approach
to guide exercise intensity is not valid and should be replaced with rating of perceived exertion set at 11-14 (on a
6- to 20-point scale)56; (b) resistance training can play an
important role in attenuating/reversing the losses in bone
mineral content and muscle strength/endurance that often
occurs among patients taking long-term corticosteroids to
suppress immune function; and (c) like other patients with
a median sternotomy, emphasize range of motion and withhold ballistic-type, upper extremity exercises until sternal
healing is completed at 6-8 wk after surgery.
HYBRID CARDIAC REHABILITATION
The use of hybrid CR, which is a patient-individualized approach that utilizes a combination of both in-facility CR and
the synchronized audiovisual (eg, telehealth) supervised exercise conducted at home or in the community, is gaining increased acceptance,57-59 including among patients with stable
HFrEF.60,61 That said, because these patients can represent
a cohort considered to be at some level of increased risk for

experiencing a complication during exercise, clinical discretion is advised relative to ensuring the safety of exercising
at home. The HF-ACTION trial demonstrated no safety
concerns among patients with HFrEF36 relative to risk for
an adverse event during or within 3 hr of exercise, including
among patients with an implantable cardioverter defibrillator.62 Although prior research involving telehealth-based
CR in patients with HFrEF demonstrates improvements in
exercise capacity and quality of life,60,61 additional information is needed to further address safety; its effect on clinical
outcomes; best methods of delivery and role for adjunctive
technology; financial viability; scalability and customizability; burden on patients and staff; and data security.57,63

SUMMARY
Heart failure with reduced ejection fraction is a disorder
that is easily diagnosed and associated with well-defined
treatment guidelines. Unfortunately, however, few patients
with HFrEF enroll in CR and as such, many partially or fully miss the benefits garnered from an evidence-based guideline therapy. Such benefits include improved exercise capacity, a likely reduction in risk for subsequent clinical events
(eg, rehospitalization), improved HRQoL, and adoption of
disease management strategies.
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